The Q1 earnings are a non-event, the stock will trade on the SOL-1 data and NDA timeline. Watch the June 17 Investor Day for regulatory updates and NDA submission clarity. The cash runway into 2028 removes near-term financing risk.
OCUL drugs
OCUL drug pipeline →Price Chart
Executive Summary
Ocular Therapeutix reported Q1 2026 net revenue of $10.8M (up 0.8% YoY), essentially flat, and a net loss of -$0.40/share, which was a 5.3% miss vs the -$0.38 loss in Q1 2025. The core financials are weak, but the stock is driven entirely by the positive SOL-1 Phase 3 data for AXPAXLI in wet AMD, which showed superiority over aflibercept. The company is on track to submit an NDA, and cash of $666.7M funds operations into 2028. The quarter itself is a non-event financially; the narrative is about the pipeline.
Key Financial Metrics
Key Facts
- Q1 2026 total net revenue $10.8M, up 0.8% from $10.7M in Q1 2025.
- Net loss of -$88.6M (-$0.40/share) vs -$64.1M (-$0.38/share) in Q1 2025.
- Cash and cash equivalents $666.7M as of March 31, 2026, with runway into 2028.
- SOL-1 Phase 3 superiority trial met primary endpoint (p=0.0006); 74.1% of AXPAXLI-treated subjects maintained vision at Week 36 vs 55.8% for aflibercept.
- NDA submission for AXPAXLI in wet AMD remains on track, subject to FDA discussions.
- SOL-R Phase 3 non-inferiority trial on track for topline data in Q1 2027.
- R&D expenses surged to $66.2M from $42.9M YoY due to clinical trial costs.
- No consensus estimates provided for Q1 2026; EPS of -$0.40 compares to prior year loss of -$0.38.
Financial Impact
Revenue essentially flat YoY; net loss widened by 38% to -$88.6M; cash burn of ~$70M in the quarter.
Risk Factors
- FDA may not accept a single pivotal trial for NDA submission.
- SOL-R non-inferiority trial results (Q1 2027) could disappoint.
- DEXTENZA revenue continues to decline due to reimbursement headwinds.
- Operating losses are widening as R&D spending increases.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055241 |
| Document: tm2613442d1_8k.htm | 0001104659-26-055241 |
| Document: 0001104659-26-055241-index-headers.html | 0001104659-26-055241 |
| Document: 0001104659-26-055241-index.html | 0001104659-26-055241 |
| Document: 0001104659-26-055241.txt | 0001104659-26-055241 |
| 8-K Data (Synthetic) | 0001104659-26-055241 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers